AbbVie Inc. Capital expenditures

Capital expenditures of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Capital expenditures growth rates and interactive chart. Capital expenditures, commonly known as Capex, are funds used by a company to acquire, upgrade, and maintain physical or intangible assets such as property, buildings, an industrial plant, technology, software or equipment. Capex is often used to undertake new projects or investments by the firm. A company must invest over its lifetime into productive assets to maintain its competitiveness and ensure its survival.


Highlights and Quick Summary

  • Capital expenditures for the quarter ending December 30, 2019 was $-163 Million (a 5.84% increase compared to previous quarter)
  • Year-over-year quarterly Capital expenditures increased by 52.34%
  • Annual Capital expenditures for 2019 was $-552 Million (a -13.48% decrease from previous year)
  • Annual Capital expenditures for 2018 was $-638 Million (a 20.6% increase from previous year)
  • Annual Capital expenditures for 2017 was $-529 Million (a 10.44% increase from previous year)
  • Twelve month Capital expenditures ending December 30, 2019 was $-552 Million (a 7.81% increase compared to previous quarter)
  • Twelve month trailing Capital expenditures decreased by -11.82% year-over-year
Trailing Capital expenditures for the last four month:
30 Dec '19 29 Sep '19 29 Jun '19 30 Mar '19
$-552 Million $-512 Million $-640 Million $-626 Million
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Capital expenditures of AbbVie Inc.

Most recent Capital expendituresof ABBV including historical data for past 10 years.

Interactive Chart of Capital expenditures of AbbVie Inc.

AbbVie Inc. Capital expenditures for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 $-163.0 $-154.0 $-128.0 $-107.0 $-552.0
2018 $-123.0 $-282.0 $-114.0 $-119.0 $-638.0
2017 $-182.0 $-126.0 $-126.0 $-95.0 $-529.0
2016 $-114.0 $-113.0 $-131.0 $-121.0 $-479.0
2015 $-145.0 $-127.0 $-115.0 $-145.0 $-532.0
2014 $-153.0 $-180.0 $-142.0 $-137.0 $-612.0
2013 $-151.0 $-133.0 $-119.0 $-88.0 $-491.0
2012 $-95.0 $18.0 $-94.0 $-162.0 $-333.0
2011 $-104.41 $-63.17 $-91.09 $-96.85 $-356.0
2010 $-448.14 $-448.0
2009 $-312.56 $-312.57

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.